119 related articles for article (PubMed ID: 37934043)
21. Low-dose narrow-band UVB phototherapy combined with topical therapy is effective in psoriasis and does not inhibit systemic T-cell activation.
de Rie MA; Out TA; Bos JD
Dermatology; 1998; 196(4):412-7. PubMed ID: 9669117
[TBL] [Abstract][Full Text] [Related]
22. Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D; Bianchi L; Fabbrocini G; Corrao S; Offidani A; Stingeni L; Costanzo A; Pellacani G; Peris K; Bardazzi F; Argenziano G; Ruffolo S; Dapavo P; Carrera C; Fargnoli MC; Parodi A; Romanelli M; Malagoli P; Talamonti M; Megna M; Raspanti M; Paolinelli M; Hansel K; Narcisi A; Conti A; De Simone C; Chessa MA; De Rosa A; Provenzano E; Ortoncelli M; Moltrasio C; Fidanza R; Burlando M; Tonini A; Gaiani FM; Simoni L; Ori A; Fiocchi M; Zagni E
Dermatol Ther; 2022 Jan; 35(1):e15166. PubMed ID: 34676662
[TBL] [Abstract][Full Text] [Related]
23. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
24. Epidermal barrier and oxidative stress parameters improve during in 311 nm narrow band UVB phototherapy of plaque type psoriasis.
Darlenski R; Hristakieva E; Aydin U; Gancheva D; Gancheva T; Zheleva A; Gadjeva V; Fluhr JW
J Dermatol Sci; 2018 Jul; 91(1):28-34. PubMed ID: 29610017
[TBL] [Abstract][Full Text] [Related]
25. Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry.
McLean RR; Sima AP; Beaty S; Low R; Spitzer RL; Stark JL; Lesser E; Lee E; Armstrong A
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2739-2751. PubMed ID: 37755689
[TBL] [Abstract][Full Text] [Related]
26. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3.
Reich K; Hansen JB; Puig L; Konstantinou MP; Warren RB
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2034-2044. PubMed ID: 34076919
[TBL] [Abstract][Full Text] [Related]
27. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2022 May; 5(5):CD011535. PubMed ID: 35603936
[TBL] [Abstract][Full Text] [Related]
28. Serum Fatty Acid-Binding Protein 4 is Increased in Patients with Psoriasis.
Baran A; Świderska M; Bacharewicz-Szczerbicka J; Myśliwiec H; Flisiak I
Lipids; 2017 Jan; 52(1):51-60. PubMed ID: 27864793
[TBL] [Abstract][Full Text] [Related]
29. The effect of topical treatment and psoriasis severity on serum retinol-binding protein-4 levels.
Baran A; Swiderska M; Flisiak I
J Dermatolog Treat; 2016; 27(2):114-9. PubMed ID: 26293108
[TBL] [Abstract][Full Text] [Related]
30. Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapy.
Strober BE; Poulin Y; Teller C; Wang Y; Williams DA; Goldblum OM
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1701-6. PubMed ID: 24422992
[TBL] [Abstract][Full Text] [Related]
31. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.
Muramatsu S; Kubo R; Nishida E; Morita A
Mod Rheumatol; 2017 Jan; 27(1):137-141. PubMed ID: 27194220
[TBL] [Abstract][Full Text] [Related]
32. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
33. Effect of psoriasis activity and topical treatment on serum lipocalin-2 levels.
Baran A; Świderska M; Myśliwiec H; Flisiak I
J Dermatolog Treat; 2017 Mar; 28(2):136-140. PubMed ID: 27165470
[TBL] [Abstract][Full Text] [Related]
34. Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis.
He Z; Jin L; Liu ZF; Hu L; Dang EL; Feng ZZ; Li QJ; Wang G
Br J Dermatol; 2012 Jul; 167(1):191-3. PubMed ID: 22356196
[TBL] [Abstract][Full Text] [Related]
35. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
Mahil SK; Wilson N; Dand N; Reynolds NJ; Griffiths CEM; Emsley R; Marsden A; Evans I; Warren RB; Stocken D; Barker JN; Burden AD; Smith CH;
Br J Dermatol; 2020 May; 182(5):1158-1166. PubMed ID: 31286471
[TBL] [Abstract][Full Text] [Related]
36. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
37. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Guelimi R; Garcia-Doval I; Hua C; Hughes C; Naldi L; Kinberger M; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011535. PubMed ID: 37436070
[TBL] [Abstract][Full Text] [Related]
38. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of biologic therapies in psoriasis vulgaris.
Mala R; Fida M; Jorgaqi E; Vasili E
Dermatol Ther; 2019 Jul; 32(4):e12936. PubMed ID: 30983095
[TBL] [Abstract][Full Text] [Related]
40. Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry.
McLean RR; Sima AP; Beaty S; Jones EA; Eckmann T; Low R; McClung L; Spitzer RL; Stark J; Armstrong A
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2753-2768. PubMed ID: 37759099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
